Pathophysiology, risk stratification, and management of sudden cardiac death in coronary artery disease

Cardiology Journal

Volumn 17, Issue 1, 2010, Pages 4-10

  El Sherif, Nabil ^a   Khan, Abdullah ^a   Savarese, Joseph ^a   Turitto, Gioia ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Diabetes and sudden cardiac death; Genetics; Post infarction remodeling; Sudden cardiac death cascade; Systolic dysfunction; The autonomic nervous system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL L TYPE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 6; OMAPATRILAT; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN C; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA;

ATHEROSCLEROSIS; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DIABETES MELLITUS; DISEASE PREDISPOSITION; ELECTROPHYSIOLOGY; GENE INTERACTION; GENE MUTATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; METABOLIC SYNDROME X; MORTALITY; PATHOPHYSIOLOGY; PROTEOMICS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SUDDEN DEATH; SYSTOLIC DYSFUNCTION; THROMBOGENESIS;

AUTONOMIC NERVOUS SYSTEM; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; DIABETES COMPLICATIONS; DISEASE SUSCEPTIBILITY; ELECTROPHYSIOLOGICAL PHENOMENA; HUMANS; MUTATION; MYOCARDIAL INFARCTION; RISK ASSESSMENT; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 75749118255     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. American Heart Association 2001. Heart and Stroke Statistical Update. American Heart Association, Dallas, TX, USA 2001.
2. Braunwald E. Shattuck lecture. Cardiovascular medicine at the turn of the millennium: Triumphs, concerns and opportunities. N Engl J Med, 1997; 377: 1360-1369.
3. Wang Q. Advances in the genetic basis of coronary artery disease. Curr Atherosclerosis Rep, 2005; 7: 235-241.
4. Spooner PM, Albert C, Benjamin EL et al. Sudden cardiac death, genes, and arrhythmogenesis: Consideration of new population and mechanistic approaches from a National Heart Lung, and Blood Institute Workshop, part I. Circulation, 2001; 103: 2361-2364.
5. Spooner PM, Albert C, Benjamin EL et al. Sudden cardiac death, genes, and arrhythmogenesis: Consideration of new population and mechanistic approaches from a National Heart, Lung, and Blood Institute Workshop, part II. Circulation, 2001; 103: 2447-2452.
6. Gnasso A, Motti C, Irace C. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol, 2000; 20: 1600-1605.
7. Moss AJ, Goldstein RE, Marder VJ et al. Thrombogenic factors and recurrent coronary events. Circulation, 1999; 99: 2517-2522.
8. Weiss EJ, Bray PF, Tayback M et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. NEJM, 1996; 334: 1090-1094.
9. Nakayama M,Yasue H,Yoshimura M et al. T786®C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation, 1999; 99: 2864-2870.
10. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett, 2000; 471: 45-50.
11. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation, 2002; 105: 2595-2599.
12. American Diabetes Association: diabetes facts and figures, 2000. (http://www.diabetes.org).
13. Stern MP. Diabetes and cardiovascular disease, the "common soil" hypothesis. Diabetes, 1995; 44: 396-374.
14. Balkau B, Jouven X, Ducimetiere P, Eschwege E. Diabetes as a risk of factor for sudden death. Lancet, 1999; 354: 1968-1969.
15. Hu FB, Stampfer MJ, Haffner SM, Soloman CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care, 2002; 25: 1129-1134.
16. Haffner SM. Glucose-intolerance testing in acute myocardial infarction. Lancet, 2002; 359: 2127-2128.
17. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol, 2004; 44: 2293-3000.
18. Jouven X, Zureik M, Desnos M, Guerot C, Ducimetiere P. Resting heart rate as a predictive risk factor for sudden death in middle aged men. Cardiovasc Res, 2001; 50: 373-378.
19. Singh JP, Larson MG, O'Donnell CJ, Tsuji H, Evans JC, Levy D. Heritability of heart rate variability: The Framingham Heart Study. Circulation, 1999; 99: 2251-2254.
20. Muller JE. Circadian variation and triggering of acute coronary events. Am Heart J, 1999; 137 (Part 2): 51-58.
21. Jaillon P, Simon T. Genetic polymorphism of beta-adrenergic receptors and mortality in ischemic heart disease. Therapie, 2007; 62: 1-7.
22. Jouven X, Charles MA, Desnos M, Ducimetiere P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden cardiac death in the population. Circulation, 2001; 104: 756-761.
23. Critchley HD, Taggart P, Sutton PM et al. Mental stress and sudden cardiac death: asymmetric midbrain activity as a linking mechanism. Brain, 2005; 128: 75-85.
24. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H. Functional beta3-adrenergic receptors in the human heart. J Clin Invest, 1996; 98: 556-562.
25. Vadim VF, Ilya TL. Is beta3-adrenergic receptors a new target for treatment of post-infarct ventricular tachyarrhythmias and prevention of sudden cardiac death. Heart Rhythm, 2008; 5: 298-299.
26. Rubart M, Zipes DP. Genes and cardiac repolarization: The challenge ahead. Circulation, 2005; 112: 1242-1244.
27. Friedlander Y, Siscovick DS, Weinmann S et al. Family history as a risk factor for primary cardiac arrest. Circulation, 1998; 97: 155-160.
28. Jouven X, Desnos M, Guerot C, Ducimetiere P. Predicting sudden death in the population: The Paris Prospective Study I. Circulation, 1999; 99: 1978-1983.
29. Friedlander Y, Siscovick DS, Arbogast P et al. Sudden cardiac death and myocardial infarction in first degree relatives as predictors of primary cardiac arrest. Atherosclerosis, 2002; 162: 211-216.
30. Lukas RCD, Connie RB, Jose PSH et al. Familial sudden death is an important risk factor for primary ventricular fibrillation. A case-control study in acute myocardial infarction patients. Circulation, 2006; 114: 1140-1145.
31. El-Sherif N, Turitto G. Risk stratification and management of sudden cardiac death: A new paradigm. J Cardiovasc Eletrophysiol, 2003; 14: 1-7.
32. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol, 1991; 260: H1406-H1414.
33. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev, 1999; 79: 215-262.
34. Hefti MA, Harder BA, Eppenberger HM, Schaub MC. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol, 1997; 29: 2873-2892.
35. Sutton MG, St J, Sharpe N. Left ventricular remodeling after myocardial infarction. Pathophysiology and therapy. Circulation, 2000; 101: 2981-2988.
36. Qin D, Zang ZH, Caref EB, Boutjdir M, Jain P, El-Sherif N. Cellular and ionic basis of arrhythmias in post infarction remodeled ventricular myocardium. Circ Res, 1996; 79: 461-473.
37. + channel genes in left ventricular remodeled myocardium after experimental myocardial infarction. Circ Res, 1996; 79: 669-675.
38. Deng L, Huang B, Qin D, Ganguly K, El-Sherif N. Calcineurin inhibition ameliorates structural, contractile, and electrophysiological consequences of post-infarction remodeling. J Cardiovasc Electrophysiol, 2001; 12: 1055-1061.
39. El-Adawi H, Deng L, Tramontano A et al. The functional role of the JAK-STAT pathway in post infarction remodeling. Cardiovasc Res, 2003; 58: 126-135.
40. + channel genes and currents in the post infarction heart. J Cardiovasc Electrophysiol, 2000; 11: 1252-1261.
41. Gyamlani G, Parikh G, Kulkani AG. Benefits of magnesium in acute myocardial infarction. Timing is crucial. Am Heart J, 2000; 139: e2.
42. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEJM, 1999; 341: 709-717.
43. Lorell BH. Transition from hypertrophy to failure. Circulation, 1997; 96: 2824.
44. Carson P. Current reviews of heart failure trials. Cardiology, 2001; 7: 27-32.
45. Berger R, Huelsmon M, Strecker K et al. Beta-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation, 2002; 105: 2392-2397.
46. Bradley DJ, Bradely EA, Baughman KL et al. Cardiac resynchronization and death frm progressive heart failure: A meta-analysis of randomized controlled trials. JAMA 2003; 289: 730-740.
47. Saavedra WF, Tunin RS, Paolocci N et al. Reverse remodeling and enhanced adrenergic reserve from passive external support in experimental dilated heart failure. J Am Coll Cardiol, 2002; 39: 2069-2076.
48. Frazier OH, Benedict CR, Radovancevic B et al. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg, 1996; 62: 675-682.
49. Hajjar RT, del Monte F, Matsui T, Rosenweig A. prospects for gene therapy of heart failure. Circ Res, 2000; 86: 616-621.
50. McClellan MB, Tunis SR. Medicare coverage of ICDs. NEJM, 2005; 352: 222-224.
51. Moss AJ, Zareba W, Hall WJ et al. prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEJM, 2002; 346: 877-883.
52. Brady GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. NEJM, 2005; 352: 225-237.
53. Honloser SH, Kuck KH, Dorian P et al. Prophylactic use of implantable cardioverter-defibrillator after myocardial infarction. NEJM, 2004; 352: 2481-2488.
54. Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. NEJM, 2008; 395: 2245-2253.
55. Yan AT, Shayne AJ, Brown KA et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation, 2006; 114: 32-39.
56. Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterly T, Tsuyuki RT. Effect of fish oil on arrhythmias and mortality: Systematic review. BMJ, 2008; 23: 337-a2931-99.